Drug Development

Low-profile Thar Pharma takes a $50M flier on a weak IPO market

The biotech IPO market has been showing signs of life lately. But that offers no guarantees for Thar Pharmaceuticals, a virtual biotech far off the industry’s beaten path pushing a reformulated pain med that so far has only been tried in a tiny safety study.

Thar’s S-1 notes that the Pittsburgh-based company has raised about $16.5 million so far, enough to pay for a Phase I study of T121, an oral formulation of the IV pain med zoledronic acid. It’s their only pipeline drug.

The big idea at little Thar has been to take its new version of the pain drug to the threshold of a pair of small Phase III studies for a rare condition called complex regional pain syndrome, or CRPS. The Pittsburgh Post-Gazette reported back in January that Thar has 7 staffers.

The biotech is looking to the public markets for $50 million to pay for the late-stage studies. As of the end of H1, Thar had $1.4 million in cash and had burned through close to $20 million. That’s not the kind of profile that’s merited much response on Wall Street.

Get Endpoints News in your inbox

Newsletters for those who discover, develop, and market drugs. Enjoy the news with the story intact — entire articles in your inbox, no clicks required. Join 12,000+ biopharma pros who read Endpoints News every day. Free subscription.


Subscribe to Endpoints

John Carroll, Editor and Co-Founder

We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.

Early Edition is a skimmable digest of original sources you need to see by ~7:15a ET, and our Main Edition is the daily chronicle of biotech, with every story inside the email ~11:55a ET.
2x/weekdays. Privacy policy